Considering the substantial co-expression of CD27 and CD26, a considerable decline in the proportion of CD26+CD8+ T cells may deprive CLL patients of the potent anti-tumor activity of this T cell subset [64]. The gene discussed is CD8A; the disease is B-cell chronic lymphocytic leukemia.